A Study to Compare the Safety and Effectiveness of Two Dosing Schedules of Lamivudine in Combination With Two Other Anti-HIV Drugs

Inclusion Criteria

• •Patients may be eligible for this study if they:
• •Are HIV-positive.
• •Are at least 18 years old.
• •Have had an HIV level below 400 copies/ml for at least 3 months prior to study entry.
• •Have a CD4 cell count of at least 50 cells/mm3.
• •Are currently taking an anti-HIV drug regimen that includes 3TC plus d4T plus either IDV or NFV for at least 6 months prior to study entry. (Note: This must be their first anti-HIV drug regimen.)
• •Agree to abstain from sex or use effective methods of birth control during the study.